Surrozen, Inc.
(NASDAQ : SRZN)

( )
SRZN PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
REGNRegeneron Pharmaceuticals, Inc. -1.85%731.862.6%$754.70m
AMGNAmgen, Inc. -1.23%230.941.4%$608.51m
MRNAModerna, Inc. -0.37%125.150.0%$589.94m
BIIBBiogen, Inc. 0.22%262.261.8%$580.04m
GILDGilead Sciences, Inc. -0.76%64.951.0%$550.05m
VRTXVertex Pharmaceuticals, Inc. -1.12%298.631.9%$429.92m
ILMNIllumina, Inc. -2.65%212.723.2%$410.84m
SNSSSunesis Pharmaceuticals, Inc. -1.47%4.020.7%$281.01m
SAVACassava Sciences, Inc. 3.37%42.350.0%$189.68m
BNTXBioNTech SE 0.25%137.530.0%$109.40m
TECHBio-Techne Corp. 0.17%309.084.5%$100.77m
BMRNBioMarin Pharmaceutical, Inc. 2.18%91.484.2%$95.92m
NVAXNovavax, Inc. -3.32%18.0875.6%$79.49m
PRTAProthena Corp. Plc 0.79%58.5713.8%$79.21m
SNTISenti Biosciences, Inc. 23.49%6.520.0%$78.99m

Company Profile

Surrozen, Inc. is a preclinical stage biotechnology company, which engages in discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. It is also focused on developing tissue-specific antibodies designed to engage the body's existing biological repair mechanisms with potential application across multiple disease areas, including inflammatory bowel disease, hepatitis, eye diseases, hearing loss, lung and airway diseases, and certain neurological disorders. The company was founded on August 12, 2015 and is headquartered in South San Francisco, CA.